Additionally, screening for germline mutations in BRCA1/BRCA2 is also a promising method for early detection of ovarian cancer in current clinical practice since high risk populations with corresponding mutations could be genetically predisposed toward developing cancer. The gene discussed is BRCA2; the disease is ovarian carcinoma.